🚀 VC round data is live in beta, check it out!
Zelgen Biopharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zelgen Biopharmaceuticals and similar public comparables like Amoytop Biotech, Tango Therapeutics, ACADIA Pharmaceuticals, Travere Therapeutics and more.
Zelgen Biopharmaceuticals Overview
About Zelgen Biopharmaceuticals
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Founded
2009
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$4B
Zelgen Biopharmaceuticals Financials
Zelgen Biopharmaceuticals reported last 12-month revenue of $176M and EBITDA of $10M.
In the same LTM period, Zelgen Biopharmaceuticals generated $162M in gross profit, $10M in EBITDA, and $10M in net income.
Revenue (LTM)
Zelgen Biopharmaceuticals P&L
In the most recent fiscal year, Zelgen Biopharmaceuticals reported revenue of $119M and EBITDA of ($14M).
Zelgen Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $176M | XXX | $119M | XXX | XXX | XXX |
| Gross Profit | $162M | XXX | $107M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $10M | XXX | ($14M) | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | (12%) | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | (20%) | XXX | XXX | XXX |
| Net Profit | $10M | XXX | ($24M) | XXX | XXX | XXX |
| Net Margin | 6% | XXX | (20%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zelgen Biopharmaceuticals Stock Performance
Zelgen Biopharmaceuticals has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Zelgen Biopharmaceuticals' stock price is $14.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -2.7% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZelgen Biopharmaceuticals Valuation Multiples
Zelgen Biopharmaceuticals trades at 21.0x EV/Revenue multiple, and 357.7x EV/EBITDA.
EV / Revenue (LTM)
Zelgen Biopharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Zelgen Biopharmaceuticals has market cap of $4B and EV of $4B.
Equity research analysts estimate Zelgen Biopharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zelgen Biopharmaceuticals has a P/E ratio of 372.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 21.0x | XXX | 31.2x | XXX | XXX | XXX |
| EV/EBITDA | 357.7x | XXX | (267.3x) | XXX | XXX | XXX |
| EV/EBIT | 309.7x | XXX | (152.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 22.8x | XXX | 34.5x | XXX | XXX | XXX |
| P/E | 372.4x | XXX | (162.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (120.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zelgen Biopharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zelgen Biopharmaceuticals Margins & Growth Rates
Zelgen Biopharmaceuticals' revenue in the last 12 month grew by 84%.
Zelgen Biopharmaceuticals' rule of 40 is 198% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zelgen Biopharmaceuticals' rule of X is 446% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Zelgen Biopharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 84% | XXX | 166% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | (12%) | XXX | XXX | XXX |
| EBITDA Growth | 707% | XXX | (827%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 198% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 446% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 43% | XXX | 57% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 40% | XXX | 53% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 115% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zelgen Biopharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zelgen Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Amoytop Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Tango Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ACADIA Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Travere Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Camurus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zelgen Biopharmaceuticals M&A Activity
Zelgen Biopharmaceuticals acquired XXX companies to date.
Last acquisition by Zelgen Biopharmaceuticals was on XXXXXXXX, XXXXX. Zelgen Biopharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zelgen Biopharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZelgen Biopharmaceuticals Investment Activity
Zelgen Biopharmaceuticals invested in XXX companies to date.
Zelgen Biopharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Zelgen Biopharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zelgen Biopharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zelgen Biopharmaceuticals
| When was Zelgen Biopharmaceuticals founded? | Zelgen Biopharmaceuticals was founded in 2009. |
| Where is Zelgen Biopharmaceuticals headquartered? | Zelgen Biopharmaceuticals is headquartered in China. |
| Is Zelgen Biopharmaceuticals publicly listed? | Yes, Zelgen Biopharmaceuticals is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals trades under 688266 ticker. |
| When did Zelgen Biopharmaceuticals go public? | Zelgen Biopharmaceuticals went public in 2020. |
| Who are competitors of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals main competitors are Amoytop Biotech, Tango Therapeutics, ACADIA Pharmaceuticals, Travere Therapeutics. |
| What is the current market cap of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals' current market cap is $4B. |
| What is the current revenue of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals' last 12 months revenue is $176M. |
| What is the current revenue growth of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals revenue growth (NTM/LTM) is 84%. |
| What is the current EV/Revenue multiple of Zelgen Biopharmaceuticals? | Current revenue multiple of Zelgen Biopharmaceuticals is 21.0x. |
| Is Zelgen Biopharmaceuticals profitable? | Yes, Zelgen Biopharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals' last 12 months EBITDA is $10M. |
| What is Zelgen Biopharmaceuticals' EBITDA margin? | Zelgen Biopharmaceuticals' last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Zelgen Biopharmaceuticals? | Current EBITDA multiple of Zelgen Biopharmaceuticals is 357.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.